221) Beyond the expansion of the RSTS-EP300-mutated cohort, this study indicates that EP300-related RSTS cases occur more frequently than previously thought (˜8% vs 3-5%); furthermore, the characterization of novel EP300 mutations in RSTS patients will enhance the clinical practice and genotype-phenotype correlations. |
PMID:24476420 DOI:10.1111/cge.12348 |
2015 Clinical genetics |
* Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene. |
- Rubinstein-Taybi syndrome (RSTS) is a rare congenital neurodevelopmental disorder characterized by postnatal growth deficiency, skeletal abnormalities, dysmorphic features and cognitive deficit. Mutations in two genes, CREBBP and EP300, encoding two homologous transcriptional co-activators, have been identified in ˜55% and ˜3-5% of affected individuals, respectively. To date, only eight EP300-mutated RSTS patients have been described and 12 additional mutations are reported in the database LOVD. In this study, EP300 analysis was performed on 33 CREBBP-negative RSTS patients leading to the identification of six unreported germline EP300 alterations comprising one deletion and five point mutations. All six patients showed a convincing, albeit mild, RSTS phenotype with minor skeletal anomalies, slight cognitive impairment and few major malformations. Beyond the expansion of the RSTS-EP300-mutated cohort, this study indicates that EP300-related RSTS cases occur more frequently than previously thought (˜8% vs 3-5%); furthermore, the characterization of novel EP300 mutations in RSTS patients will enhance the clinical practice and genotype-phenotype correlations. |
(1)22 therapeutic | (17)3 mutation | (33)2 approaches | (49)2 information |
(2)11 and | (18)3 paradigm | (34)2 autosomal | (50)2 inhibitors |
(3)8 mechanism | (19)3 role | (35)2 candidate | (51)2 learning |
(4)8 method | (20)3 strain | (36)2 cardiac | (52)2 modulators |
(5)7 approach | (21)3 target | (37)2 clinical | (53)2 object |
(6)7 mutations | (22)3 targeted | (38)2 compounds | (54)2 oral |
(7)6 therapies | (23)3 targets | (39)2 data | (55)2 polymer |
(8)5 technique | (24)3 treatment | (40)2 described | (56)2 potent |
(9)4 strategies | (25)3 type | (41)2 dual | (57)2 prognostic |
(10)4 strategy | (26)3 words | (42)2 electroporation | (58)2 putative |
(11)4 surgical | (27)2 *null* | (43)2 finding | (59)2 recombinants |
(12)3 antibacterial | (28)2 anti-tumor | (44)2 findings | (60)2 results |
(13)3 drug | (29)2 antibiotic | (45)2 form | (61)2 therapeutical |
(14)3 homozygous | (30)2 anticancer | (46)2 genetic | (62)2 titanium |
(15)3 insights | (31)2 application | (47)2 imaging | (63)2 treatments |
(16)3 mechanisms | (32)2 applications | (48)2 in |
add keyword